Abbott Laboratories에 대한 매도 수량은 투자자에게 Abbott Laboratories의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Abbott Laboratories (NYSE:ABT) 주식, 공매도 수량 보고

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Fear and Greed

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NFLX

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

CNN 머니 공포·탐욕 지수는 수요일(16일) &#39;극도의 공포&#39; 영역에 머물렀지만 전반적인 공포 수준이 더 상승한 것으로 나타났다.수요일 미국 증시는 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승 및 성장 둔화와 연결시키면서 연준이 시장 손실을 완화할 의사가 없음을 분명히 한 후 다우존스 지수가 장중 약 700포인트 하락하는 등 하락세로 마감했다.

엔비디아·AMD 급락으로 나스닥 3% 하락: 탐욕 지수는 &#39;극도의 공포&#39; 영역 유지

wall street, mercados estadounidenses

Equities

Government

Large Cap

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

FANG

JBHT

KLAC

PLTR

수요일(16일) 오후 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승과 성장 둔화에 연결시키면서 연준이 시장 손실을 완화할 의사가 없음을 분명히 한 후 위험심리는 급격한 타격을 입었다.

파월 의장, &#39;연준 풋&#39; 기대 일축···미국 증시 하락, 금 상승세 확대

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

CNN 머니 공포·탐욕 지수는 전반적인 공포 수준이 증가했음을 보여 주었고, 지수는 화요일에 &#34;극단적 공포&#34; 영역에 머물렀다.화요일(15일) 미국 증시는 하락세로 마감했고, 특히 다우존스 지수는 투자자들이 최근 실적 보고서를 평가하는 동안 세션 중 150포인트 이상 하락했다.

시티·뱅크오브아메리카 수익 예상치 상회, 다우 150포인트 이상 하락: 탐욕 지수 &#39;극단적 공포&#39; 영역 유지

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77%, but in the past year, increased by 22.07%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_0.png" alt="Past Year Chart" />

<h3>How Does Abbott Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 59.36 in the Health Care Equipment &amp; Supplies industry, Abbott Laboratories Inc. has a lower P/E ratio of 16.87. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Abbott Laboratories Inc's Price Over Earnings

<ul>
<li>Long-term data from the Volt&nbsp;CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt&#x2122; PFA System</li>
<li>The 12-month results of the Volt&nbsp;CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System</li>
<li>The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting</li>
</ul>

Reported Saturday, Abbott Presents New Volt PFA System Data Highlighting Outstanding Long-Term Safety And Freedom From Arrhythmia At 12 Months

<ul>
<li>Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker</li>
<li>Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead</li>
<li>Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm</li>
</ul>

Reported Sunday, Abbott's AVEIR CSP Study Demonstrates First Successful Leadless Conduction System Pacing In Left Bundle Branch Area

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$52.0K</td>
<td>100</td>
<td>4.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$33.3K</td>
<td>3.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$134.3K</td>
<td>992</td>
<td>550</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$17.50</td>
<td>$26.6K</td>
<td>20</td>
<td>401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$780.00</td>
<td>$25.9K</td>
<td>1.0K</td>
<td>384</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$25.0K</td>
<td>4.4K</td>
<td>262</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>897</td>
<td>233</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$70.00</td>
<td>$61.9K</td>
<td>336</td>
<td>39</td>
</tr>
<tr>
<td>MTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1180.00</td>
<td>$58.8K</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 100 contract(s) at a $450.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 100 open contracts at this strike prior to today, and today 4332 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option sweep that happens to be bullish, expiring in 273 day(s) on January 16, 2026. This event was a transfer of 34 contract(s) at a $50.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $980.0 per contract. There were 3960 open contracts at this strike prior to today, and today 1145 contract(s) were bought and sold. 
• For BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we notice a call option sweep that happens to be bearish, expiring in 28 day(s) on May 16, 2025. This event was a transfer of 363 contract(s) at a $105.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $134.3K, with a price of $370.0 per contract. There were 992 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we observe a put option trade with bearish sentiment. It expires in 28 day(s) on May 16, 2025. Parties traded 140 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $190.0 per contract. There were 20 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on April 17, 2025. This event was a transfer of 4 contract(s) at a $780.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $6480.0 per contract. There were 1032 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• Regarding SLNO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), we observe a call option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 50 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 4483 open contracts at this strike prior to today, and today 262 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 637 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $1050.0 per contract. There were 897 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a put option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 38 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $61.9K, with a price of $1630.0 per contract. There were 336 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold. 
• Regarding MTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), we observe a call option trade with bearish sentiment. It expires in 182 day(s) on October 17, 2025. Parties traded 12 contract(s) at a $1180.00 strike. The total cost received by the writing party (or parties) was $58.8K, with a price of $4900.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option trade that happens to be neutral, expiring in 336 day(s) on March 20, 2026. This event was a transfer of 5 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $5814.0 per contract. There were 10 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BHVN

BNTX

SLNO

SRPT

10 Health Care Stocks Whale Activity In Today's Session

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $132 to $142.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $142

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $133 to $145.

Reiteration

Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $145

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $140 to $145.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $136 to $147.

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $147

Morgan Stanley analyst David Lewis maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Equal-Weight and raises the price target from $117 to $127.

Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $127

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/abt/earnings">adjusted EPS results</a> on Wednesday.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.
These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.
<ul>
<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>
<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>
<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png" alt="" class="wp-image-877000" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44866413/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $158 to $159.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $159

11 analysts have shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.82, a high estimate of $160.00, and a low estimate of $135.00. This upward trend is apparent, with the current average reflecting a 5.92% increase from the previous average price target of $136.73.
<img src="https://www.benzinga.com/files/images/story/2025/1744898414_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Abbott Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $145.00&#x7C;$135.00 &#x7C; 
&#x7C;Matthew Taylor &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $137.00&#x7C;$135.00 &#x7C; 
&#x7C;Travis Steed &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $150.00&#x7C;$133.00 &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $160.00&#x7C;$135.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $154.00&#x7C;$138.00 &#x7C; 
&#x7C;Matt Miksic &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $158.00&#x7C;$149.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C; 
&#x7C;Lawrence Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $136.00&#x7C;$133.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $135.00&#x7C;$130.00 &#x7C; 
&#x7C;Danielle Antalffy &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $148.00&#x7C;$146.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Abbott Laboratories's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Abbott Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>A Deep Dive into Abbott Laboratories's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Abbott Laboratories displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 84.1%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.1%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 11.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $145.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $145

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $135 to $137.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $137

U.S. stock futures rose on Thursday ahead of the long weekend, with Good Friday falling on April 18 and Easter Sunday on April 20. Futures of major benchmark indices were higher in premarket.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation">Federal Reserve</a> Chairman Jerome Powell dismissed the possibility of a &#8220;Fed put&#8221; in the near term while speaking in Chicago on Wednesday.
&#8220;We may find ourselves in the challenging scenario in which our dual-mandate goals are in tension. If that were to occur, we would consider how far the economy is from each goal, and the potentially different time horizons over which those respective gaps would be anticipated to close,&#8221; said Powell.
U.S. export restrictions on Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://benzinga.com/25/04/44844084/nvidias-h20-chip-ban-could-lead-to-manageable-sales-drop-bank-of-america-says">H20 GPUs</a> pulled the stock market down on Wednesday.
The 10-year Treasury bond yielded 4.32% and the two-year bond was at 3.82%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 86.4% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.75%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.83%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.66%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. The SPY was up 1.03% to $531.05, while the QQQ advanced 1.04% to $448.78, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
U.S. stocks closed sharply lower on Wednesday, driven by a significant sell-off in the semiconductor sector and broader tech weakness.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) experienced a steep decline, with Nvidia Corp. and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both falling approximately 7% following new export restrictions on Nvidia chips to China.
This news heavily impacted the information technology sector, which, along with consumer discretionary and communication services, recorded the largest losses. In contrast, energy stocks defied the overall downward trend, closing higher.
Among individual companies, Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported better-than-expected first-quarter results, and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) posted upbeat first-quarter adjusted EPS.
On the economic front, U.S. industrial production fell by 0.3% in March, slightly more than anticipated. However, U.S. retail sales surged 1.4% month-over-month in March, exceeding both the previous month&#8217;s gain and market expectations.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-3.07%</td>
<td>16,307.16</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.24%</td>
<td>5,275.70</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.73%</td>
<td>39,669.39</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.03%</td>
<td>1,863.48</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Scott Wren, the senior global market strategist at Wells Fargo, &#8220;current equity levels offer an attractive entry opportunity even with the bounce higher off the recent lows.&#8221;
Wren further emphasized the importance of having a &#8220;plan of action or at least be happy with where you currently stand,&#8221; regardless of individual perspectives on the implemented tariffs.
&#8220;Over the course of the last couple of weeks, we have seen the administration go from an aggressive reciprocal tariff strategy that involved meaningful universal tariffs on virtually all of our trading partners to a pause that suspends most reciprocal tariffs but leaves a 145% levy on imports from China,&#8221; Wren notes.
Despite the tariff uncertainty, Wren&#8217;s firm maintains a view that the U.S. economy was already heading for a slowdown in the first half of the year, even before the current trade strategies were implemented. &#8220;From our perspective, even before the current tariff strategies were deployed, our analysis suggested the economy was going to hit a bump in the road and slow in the first half of this year. That line of thought is still intact,&#8221; Wren states.
Wren also suggests a strategic shift in fixed income, advising investors to &#8220;move money from bonds, specifically the intermediate portion of the yield curve, into mid-cap U.S. equities in an effort to take advantage of the fall in stocks and the rally in bond prices (yields fell).&#8221;
Meanwhile, the <a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-currency-may-be-called-into-question-amid-tariff-turmoil">U.S. dollar is facing pressure</a>, with its &#8220;reserve currency&#8221; status. A recent study titled &#8216;Dollar Upheaval: This Time is Different&#8217; noted a 3.6% depreciation between April 4th and 14th, an unusual move as the dollar typically gains during global volatility.
This suggests a break from traditional market behavior, raising concerns that U.S. Treasuries lose their safe-haven appeal.
"If U.S. Treasuries are no longer viewed as the world's preferred safe asset, then the status of the dollar as the world's reserve currency may be called into question,&#8221; stated the note.
Investors are now <a href="https://www.benzinga.com/news/treasuries/25/04/44857989/gold-nears-3400-mark-experts-point-to-likely-correction-amid-bull-market-rates-will-drop-like-rock">flocking to Gold</a>, which has been hitting fresh highs as it trades above $3,300 per ounce. According to data shared by Charlie Bilello of Creative Planning, the inflation-adjusted gold prices were back at an all-time high, after 45 years, surpassing the prior peak from 1980.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It took 45 years to get there, but inflation-adjusted Gold prices are back at an all-time high, surpassing the prior peak from 1980. <a href="https://twitter.com/search?q=%24GOLD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOLD</a><a href="https://t.co/l5IYmkeySJ">https://t.co/l5IYmkeySJ</a> <a href="https://t.co/bXWisvrl3c">pic.twitter.com/bXWisvrl3c</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1912558536573268362?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Economist Mohamed El-Erian attributed the increasing price of gold to a gradual shift away from the U.S. dollar by some foreign central banks and other entities seeking diversification.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The price of gold registered another record high today, overcoming yet another periodic round of profit-taking by some tactical traders — this as it benefits from the tailwind of slow and steady diversification away from the dollar by some foreign central banks and others.<a href="https://twitter.com/hashtag/gold?src=hash&amp;ref_src=twsrc%5Etfw">#gold</a>… <a href="https://t.co/MKDnxZddv0">pic.twitter.com/MKDnxZddv0</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1912523089557987357?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday and Friday:
<ul>
<li>On Thursday, initial jobless claims data for the week ending April 12 and March&#8217;s housing starts, building permits, and April&#8217;s Philadelphia Fed manufacturing survey data will be released by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>On Friday, San Francisco Fed President Mary Daly will speak at 8:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell 0.64% in premarket on Thursday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $7.29 per share on revenue of $111.60 billion.</li>
</ul>
<ul>
<li>DR Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) rose 0.39% as Wall Street expects it to report earnings of $2.65 per share on revenue of $8.03 billion before the opening bell.</li>
</ul>
<ul>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) was up 1.38% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $5.72 per share on revenue of $10.52 billion.</li>
</ul>
<ul>
<li>FNB Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) was up 1.14% as it posted better-than-expected earnings for its first quarter on Wednesday.</li>
</ul>
<ul>
<li>Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) jumped 3.45% after reporting a 60% surge in its net profit for the first quarter, topping market expectations.</li>
</ul>
<ul>
<li>Rio Tinto Plc ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) climbed 1.68% after it announced the assessment of the low-carbon aluminum project in India along with AMG Metals &amp; Materials.</li>
</ul>
<ul>
<li>Woodside Energy Group Ltd. ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDS#NYSE">WDS</a>) advanced 2.73% after signing LNG supply agreements with Uniper.</li>
</ul>
<ul>
<li>BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) gained 1.08%, and Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) was 4.22% higher after BP completed loading the first cargo from the Greater Tortue Ahmeyim LNG project.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.02% to hover around $63.11 per barrel.
Gold Spot US Dollar declined 0.57% to hover around $3,324.20 per ounce. Its fresh record high stood at $3,357.81 per ounce. The U.S. Dollar Index spot was higher by 0.10% at the 99.4760 level.
Asian markets advanced on Wednesday, except China&#8217;s CSI 300 index. India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index ended higher. European markets were lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-currency-may-be-called-into-qu">Policy Push vs. Market Pull: Dollar Under Pressure As &#8216;Reserve Currency May Be Called Into Question&#8217; Amid Tariff Turmoil</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Commodities

Treasuries

US Stocks Likely To Open Higher Ahead Of Festive Weekend: 'Current Equity Levels Offer An Attractive Entry Opportunity'

The CNN Money Fear and Greed index showed a further increase in the overall fear level, while the index remained in the &#8220;Extreme Fear&#8221; zone on Wednesday.
U.S. stocks settled lower on Wednesday, with the Dow Jones index falling around 700 points during the session after Federal Reserve Chair Jerome Powell linked rising tariffs to higher inflation and slower growth, while making it clear the central bank has no intention of cushioning market losses.
Semiconductors were particularly hit hard following fresh export restrictions on Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips to China. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) fell sharply on Wednesday, with Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both down around 7%.
Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) posted better-than-expected first-quarter results on Wednesday. Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported upbeat first-quarter adjusted EPS results.
On the economic data front, U.S. industrial production declined by 0.3% in March compared to market estimates of a 0.2% fall. U.S. retail sales rose 1.4% month-over-month in March versus a 0.2% gain in the previous month and better than estimates of 1.3%.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, information technology, and communication services stocks recording the biggest losses on Wednesday. However, energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 700 points to 39,669.39 on Wednesday. The S&amp;P 500 fell 2.24% to 5,275.70, while the Nasdaq Composite dipped 3.07% to 16,307.16 during Wednesday's session.
Investors are awaiting earnings results from Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 14.4, the index remained in the &#8220;Extreme Fear&#8221; zone on Wednesday, versus a prior reading of 18.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based&nbsp;on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44836567/jim-cramer-nrg-energy-is-very-good-utility">Jim Cramer: NRG Up, Deluxe Out, Nvidia &#8216;You Have To Trim&#8217;</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Dips 3% Amid Plunge In Nvidia, AMD: Greed Index Remains In 'Extreme Fear' Zone

Risk sentiment took a sharp blow Wednesday afternoon after Federal Reserve Chair Jerome Powell linked rising tariffs to higher inflation and slower growth, while making it clear the central bank has no intention <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation">of cushioning market losses.</a>
In remarks at the Economic Club of Chicago, Powell said the inflationary effects of tariffs could be more persistent than previously thought, and warned that current policy uncertainty makes it difficult to gauge their full impact. 
Most notably for Wall Street, Powell addressed the notion of a so-called "Fed put"—the belief that the central bank would intervene if markets drop sharply—and offered a blunt response: "I'm going to say no."
That single line pushed traders to recalibrate expectations for any near-term monetary support.
<h3 class="wp-block-heading">Stocks Tumble As Chipmakers Extend Losses</h3>
By 3:15 p.m. ET, the S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – had dropped 3.1% to 5,230 points, while the Nasdaq 100 – tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) plunged 4.1% to 18,050, dragged down by the tech-heavy weighting of the index. 
The Dow Jones Industrial Average shed 838 points, or 2.1%, and the Russell 2000 small-cap index also fell 2.1%.
Nearly every sector turned red, with the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) nosediving 5%. Energy stocks were the sole exception, buoyed by higher crude prices and safe-haven commodity demand.
Semiconductors were particularly hard hit following fresh export restrictions on Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips to China. 
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) plummeted 6.8%, with Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both down around 10%.
<h3 class="wp-block-heading">Gold Shines In Flight To Safety</h3>
As stocks tumbled, gold prices climbed, continuing their powerful 2025 rally. The precious metal hit new record highs, rising to over $2,350 an ounce, and is now up 26% year to date. 
With the Nasdaq 100 down 23% over the same period, gold has outperformed the tech index by nearly 50% in less than four months.
Gold's appeal has grown amid mounting inflation concerns, policy uncertainty, and geopolitical tension.
<h3 class="wp-block-heading">Powell: No Market Rescue This Time</h3>
Powell's refusal to endorse the "Fed put" marked a sharp shift in tone from the central bank's more accommodative stance in past downturns. While he acknowledged market volatility, he said both equity and bond markets were "functioning" and "orderly."
"Markets are struggling with a lot of uncertainty, and that means volatility," Powell said. "But having said that, markets are functioning."
The Fed chair emphasized that rate decisions will continue to focus on economic data, especially inflation and employment, and not on asset prices.
Top S&amp;P 500 Gainers:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>129.93</td>
<td>+2.94%</td>
</tr>
<tr>
<td>APA Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>)</td>
<td>15.27</td>
<td>+2.52%</td>
</tr>
<tr>
<td>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>29.21</td>
<td>+2.40%</td>
</tr>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>55.88</td>
<td>+2.37%</td>
</tr>
<tr>
<td>Diamondback Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>)</td>
<td>129.98</td>
<td>+2.23%</td>
</tr>
</tbody>
</table>
</figure>
Top S&amp;P 500 Losers:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Micro Devices Inc.</td>
<td>85.90</td>
<td>-9.86%</td>
</tr>
<tr>
<td>Nvidia Corp.</td>
<td>101.25</td>
<td>-9.76%</td>
</tr>
<tr>
<td>J.B. Hunt Transport Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NYSE">JBHT</a>)</td>
<td>123.21</td>
<td>-8.81%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>89.90</td>
<td>-8.63%</td>
</tr>
<tr>
<td>KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>622.99</td>
<td>-7.87%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44844084/nvidias-h20-chip-ban-could-lead-to-manageable-sales-drop-bank-of-america-says">Nvidia H20 Chip Ban Could Lead To &#8216;Manageable&#8217; Sales Drop, Bank Of America Says</a></li>
</ul>
Photo: Shutterstock

Stocks Sink As Powell Dismisses 'Fed Put' Safety Net, Gold Extends Massive Lead Over Nasdaq

U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip <a href="https://www.benzinga.com/topic/china">export restrictions to China.</a>
The U.S. government has barred Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from selling its H20 chips to China — a move that could wipe out an estimated $5.5 billion from the company's projected quarterly revenue. Nvidia shares slid nearly 7%.
Other chipmakers also felt the heat. Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 6% as its MI308 chips fall under the new licensing requirements.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) sank 3.4%, extending the sector&#8217;s losses. Adding to the drag, Dutch chip equipment giant ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) missed quarterly revenue estimates, sending its shares down 5%.
On the macro front, March retail sales surprised to the upside, rising 1.4% month-over-month — topping forecasts of 1.3% and marking the strongest monthly <a href="https://www.benzinga.com/25/04/44837237/march-retail-sales-post-highest-surge-in-over-two-years-as-us-consumers-anticipate-tariff-jitters">gain since January 2023.</a>
Meanwhile, the U.S. dollar saw renewed selling pressure, with the dollar index dipping back below 100. Treasury yields were little changed, with the 10-year yield holding steady near 4.33%.
Gold continued its stellar run, surging 2.5% to a fresh record high of $3,320 per ounce as demand for safe-haven assets remains robust.
In commodities, oil prices rebounded sharply, with WTI crude climbing 2% to $62 a barrel. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also edged up 1.3% to around $84,500.
All eyes are now on Fed Chair Jerome Powell, who is set to speak at the Economic Club of Chicago later this afternoon.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,318.86</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,872.38</td>
<td>-0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,340.12</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,501.22</td>
<td>-1.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 11:30 a.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.9% to $532.68.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $403.09.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;tanked 1.7% to $450.31.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $185.84.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.1%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.2%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>5.39%</td>
</tr>
<tr>
<td>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>4.33%</td>
</tr>
<tr>
<td>The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)</td>
<td>4.17%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>3.92%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>3.84%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>)</td>
<td>-8.40%</td>
</tr>
<tr>
<td>NVIDIA Corporation </td>
<td>-6.81%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>-5.81%</td>
</tr>
<tr>
<td>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>-4.77%</td>
</tr>
<tr>
<td>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>)</td>
<td>-4.71%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44832771/the-ball-is-in-chinas-court-trump-says-as-white-house-awaits-beijings-call-china-needs-to-make-a-deal-with-us">&#8216;The Ball Is In China&#8217;s Court&#8217;: Trump Says As White House Awaits Beijing&#8217;s Call — &#8216;China Needs To Make A Deal With Us&#8217;</a></li>
</ul>
Photo: Shutterstock

Asia

Sector ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

Select Sector SPDR-Consumer Discretionary

Nvidia Drags Wall Street Down, Gold Defies Gravity Ahead Of Powell Remarks: What's Driving Markets Wednesday?

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.
The Dow traded down 0.67% to 40,099.73 while the NASDAQ dipped 2.12% to 16,466.96. The S&amp;P 500 also fell, dropping, 1.27% to 5,327.95.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44836659/top-3-industrials-stocks-that-may-plunge-this-month">Top 3 Industrials Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Energy shares surged by 1.4% on Wednesday.
In trading on Wednesday, information technology shares fell by 3%.
Top Headline
Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter adjusted EPS results.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares shot up 70% to $3.54 after the company announced that it has secured an exclusive partnership with Mezzofy to become the sole distributor of its digital coupon platform and is targeting $2-4 million in annual recurring revenue.</li>
<li>Shares of Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>)got a boost, surging 70% to $2.3097.</li>
<li>iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares were also up, gaining 67% to $3.22 after the company announced it will be acquired by RadNet for a deal worth approximately $103 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares dropped 40% to $0.0249 as the company announced a 1-for-200 reverse stock split.</li>
<li>Shares of Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) were down 35% to $2.07. Ostin Technology Group announced the pricing of $5.0 million registered direct offering.</li>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) was down, falling 30% to $0.4006 after the company announced a 1-for-8 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $62.33 while gold traded up 2.6% at $3,323.10.
Silver traded up 1.7% to $32.860 on Wednesday, while copper rose 0.1% to $4.6310.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.7%, Germany's DAX 40 declined 0.4% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index slipped 0.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 1.01%, China's Shanghai Composite gaining 0.26%, Hong Kong's Gang Seng index dipping 1.91% and India's BSE Sensex gaining 0.4%.
Economics
<ul>
<li>U.S. industrial production declined by 0.3% in March compared to market estimates of a 0.2% fall.</li>
<li>U.S. retail sales rose 1.4% month-over-month in March versus a 0.2% gain in the previous month and better than estimates of 1.3%.</li>
<li>U.S. mortgage application volumes dipped by 8.5% from the previous week during the second week of April.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44838854/nvidia-to-160-here-are-10-top-analyst-forecasts-for-wednesday">Nvidia To $160? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Eurozone

BMRA

ICAD

SUNE

Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings

Abbott Laboratories<a target="_blank" href="https://www.benzinga.com/quote/ABT" rel="noreferrer noopener">&nbsp;</a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.40 billion</a>.
First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44835060/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance" rel="noreferrer noopener">testing-related sales</a>.
The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43174107/why-is-abbott-stock-trading-higher-on-thursday" rel="noreferrer noopener">guidance of $1.05-$1.09</a>.
&#8220;Once again, Abbott&#8217;s diversified business model delivered top-tier sales and EPS growth,&#8221; said&nbsp;Robert Ford, chairman and CEO of Abbott. &#8220;It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a>
Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure and Electrophysiology.
Several products, including FreeStyle Libre, Navitor, TriClip, Amplatzer&nbsp;Amulet, and AVEIR, contributed to the strong performance.
In Diabetes Care, sales of continuous glucose monitors were&nbsp;$1.7 billion&nbsp;and grew 18.3% on a reported basis and 21.6% on an organic basis.
Nutrition sales of $2.15 billion increased 3.8% on a reported basis and 6.8% on an organic basis in the first quarter.
In Pediatric Nutrition, global sales increased 3.2% on a reported basis and 4.9% on an organic basis.
In Adult Nutrition, global sales of $1.11 billion increased 4.4% on a reported basis and 8.7% on an organic basis, which was led by strong growth of Ensure and Glucerna.
Global Diagnostics sales of $2.05 billion decreased 7.2% on a reported basis, down 4.9% on an organic basis, or increased 0.5% when excluding COVID-19 testing-related sales.
The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in&nbsp;China impacted diagnostics sales growth.
COVID-19 testing-related sales were&nbsp;$84 million&nbsp;in the quarter, compared to&nbsp;$204 million&nbsp;a year ago.
Global Core Laboratory Diagnostics sales decreased 2.3% on a reported basis and increased 0.9% on an organic basis.
Abbott&#8217;s reported operating margin was 16.3% of sales, and adjusted operating margin of 21%, which reflects a 130 basis point increase year-over-year.
Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%.
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
In March, Abbott received European approval for the Volt PFA System for atrial fibrillation (AFib). The company will further expand its use in EU markets throughout the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44513547/abbott-receives-ce-mark-for-its-volt-pulsed-field-ablation-system-to-treat-patients-with-abnormal-" rel="noreferrer noopener">second half of the year</a>.
Last month,&nbsp;Abbott also announced late-breaking data from its TRILUMINATE&nbsp;trial that show the TriClip&nbsp;transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44560892/new-late-breaking-data-reinforce-benefits-of-abbotts-triclip-for-people-with-leaky-tricuspid-heart" rel="noreferrer noopener">severity of TR after two years</a>.
Price Action:&nbsp;ABT stock is up 5.02% at $132.55 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44836101/vale-q1-mixed-iron-ore-output-falls-4-amid-heavy-rains-copper-and-nickel-output-gains" target="_blank" rel="noreferrer noopener">Vale Q1 Iron Ore Output Falls 4.5% Amid Heavy Rains, Copper And Nickel Output Gain</a></li>
</ul>
Photo via Shutterstock

Guidance

Health Care

Movers

General

Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty

Press Releases

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

Abbott Hosts Conference Call for First-Quarter Earnings

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

CVKD

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Abbott Laboratories

매도 수량

Abbott Laboratories (NYSE:ABT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌